Navigation Links
Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Date:3/26/2008

QUEBEC CITY, March 26 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced with its flagship product candidate, cetrorelix, the Company's lead luteinizing hormone-releasing hormone (LHRH) antagonist, in the second efficacy study of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate.

"We are very pleased to be on track with our Phase 3 clinical program for cetrorelix in BPH," said David J. Mazzo, Ph.D., President and CEO, Aeterna Zentaris. "Based on our new understanding of the multiple processes involved in the development of BPH and its symptoms, cetrorelix may offer a novel therapeutic approach to doctors and patients currently making trade-offs in care. We look forward to continuing our investigation of cetrorelix in this comprehensive clinical program."

The study, titled, "Cetrorelix pamoate in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", will involve approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This Phase 3 trial, conducted in Europe under the supervision of lead investigator, Prof. Dr. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, is part of the Company's Phase 3 program with cetrorelix being studied in approximately 1,500 patients in North America and Europe in men with symptomatic BPH.

About the Phase 3 Program with Cetrorelix in BPH

The first multi-center efficacy study for which first patient rand
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
2. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
3. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
4. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
5. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
6. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. AEterna Zentaris Announces Outcome of Managements Strategic Review
9. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
10. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
11. SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... compounds and metabolic processes, is pleased to announce the addition ... Ms. Nola E. Masterson , a California ... effective September 17, 2014. "We,re very pleased ... board," states Andrew Dahl , President and CEO. "She ...
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 ... Chancellor John Sharp, Texas A&M Health Science Center ... U.S. Department of Health and Human Services (HHS), ... dedicated a national pandemic influenza vaccine manufacturing facility ... as an anchor for the Texas A&M Biocorridor ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... cells are undifferentiated biological cells that can differentiate into ... more stem cells. Stem cell therapy can be applied ... hematological system disease), nervous system diseases, damage or lesion ...
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3
... high resolution structure of a nano-scale square made from ribonucleic ... in this week,s early online edition of the journal ... team of chemists headed by Thomas Hermann, an assistant professor ... the ability to carry structural information encoded in the sequence ...
... Calif., April 4, 2011 Ambry Genetics announced today ... (CSP) in Ion Torrent,s new service provider program. Ion ... are trusting with their samples has been trained and ... sequence data. (Logo: http://photos.prnewswire.com/prnh/20110307/LA59848LOGO ) ...
... April 4, 2011 Cellectis (Alternext: ALCLS), the ... a license agreement with a pharmaceutical company covering certain uses ... the oncology therapeutic field. This agreement has triggered ... Further details of the arrangement have not been disclosed. ...
Cached Biology Technology:Ambry Genetics is First Authorized Customer Service Provider in New Ion Torrent CSP Program 2Ambry Genetics is First Authorized Customer Service Provider in New Ion Torrent CSP Program 3
(Date:9/18/2014)... University and the Quebec government have discovered microplastics ... Journal of Fisheries and Aquatic Sciences . , ... or industrial cleansers, to which they are commonly ... and buoyancy, they may readily pass through sewage ... in the world,s oceans, but have only recently ...
(Date:9/18/2014)... how many times it,s demonstrated, it,s still hard ... , But by using a signaling system called ... behavior to suit their population. In short, some ... and act accordingly. , Once the population of ... from innocuous to pathogenic, or from unhelpful to ...
(Date:9/18/2014)... creatively manipulate spoken language is unique to humans. "The ... years of human evolution to make this possible are ... we now have," says Wolfgang Enard, Professor of Anthropology ... understand the molecular biological basis of language Enard has ... his latest study, undertaken in collaboration with scientists at ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... researchers have identified the culprit gene for a rare condition ... control. Their finding provides new insight into urofacial syndrome ... percent of the general population. "This paper really ... gene and its encoded proteins play a very important role ...
... diseases on crops in developing countries and their ... to a new study by Maurizio Vurro and ... of Food Production in Italy. The authors call ... better mechanisms for monitoring and managing emerging infectious ...
... Singapore (GIS), a biomedical research institute of the Agency ... from the National University of Singapore, Nanyang Technological University, ... discovered that viruses that ,invaded, the human genome millions ... turned on and off in human embryonic stem (ES) ...
Cached Biology News:Researchers identify gene linked to hereditary incontinence 2Researchers identify gene linked to hereditary incontinence 3Plant disease -- more than a crop killer 2Scientists discover ancient viral invasion that shaped human genome 2Scientists discover ancient viral invasion that shaped human genome 3
... been developed for use with immunohistochemical ... nonspecific background staining due to endogenous ... peroxidase with hydrogen peroxide. This ... with additional novel components to further ...
Anti-Human Factor XI Purified (Polyclonal) (sheep IgG)...
Formulation: 10mM PBS/500 mM NaCl, 0.09% NaN3, pH 7.2...
Rad51B...
Biology Products: